<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D. C. 20549
FORM 10-Q / A
X AMENDMENT TO QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF
- --- THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1996
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
- --- EXCHANGE ACT OF 1934
For the Transition Period from ___________ to ___________
COMMISSION FILE NUMBER 0-27540
ENDOVASCULAR TECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in its Charter)
DELAWARE 94-3096794
(State of Incorporation) (I.R.S. Employer Identification No.)
1360 O'BRIEN DRIVE
MENLO PARK, CALIFORNIA 94025
415-325-1600
(Address, Zip Code and Telephone Number of Principal Executive Offices)
Indicate by check mark whether the Registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the Registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days.
YES X NO
--- ---
The number of shares outstanding of each of the issuer's classes of common stock
as of March 31, 1996 was: 8,291,563
This document contains 5 pages and the Exhibit Index is on Page 4
Page 1 of 5
<PAGE> 2
ENDOVASCULAR TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)
TABLE OF CONTENTS
PART I. FINANCIAL INFORMATION PAGE
+Item 1. Financial Statements
Balance Sheets as of December 31, 1995 and
March 31, 1996
Statements of Operations for the Three Months Ended
March 31, 1995 and March 31, 1996
Statements of Cash Flows for the Three Months Ended
March 31, 1995 and March 31, 1996
Notes to Financial Statements
Risk Factors
+Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations
PART II. OTHER INFORMATION
+Item 6. Exhibits and Reports on Form 8-K
Signatures
Exhibit Index
+Exhibit 11 Computation of Loss Per Share
Exhibit 27 Financial Data Schedule 5
+Previously filed with Form 10-Q on May 15,1996
Page 2 of 5
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this amendment to the registrant's report on Form
10-Q to be signed on its behalf by the undersigned thereunto duly authorized.
ENDOVASCULAR TECHNOLOGIES, INC.
-------------------------------
(Registrant)
Date: July 1, 1996 /s/ W. James Fitzsimmons
------------------------------
W. James Fitzsimmons
President and
Chief Executive Officer
(Principal Executive Officer)
Date: June 28, 1996 /s/ G. Bradley Cole
------------------------------
G. Bradley Cole
Vice President, Finance and
Chief Financial Officer
(Principal Financial and Accounting Officer)
Page 3 of 5
<PAGE> 4
ENDOVASCULAR TECHNOLOGIES, INC.
(A DEVELOPMENT STAGE COMPANY)
<TABLE>
<CAPTION>
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION PAGE NO.
<S> <C> <C>
*3.1 - Form of Restated Certificate of Incorporation to be filed
upon the closing of the offering made pursuant to this
Registration Statement.
*3.2 - Bylaws of the Company to be effective upon the closing of
the offering made pursuant to this Registration Statement.
*4.1 - Reference is made to Exhibits 3.1 and 3.2.
*4.2 - Specimen Common Stock certificate.
*4.3 - Fourth Amended and Restated Investor Rights Agreement, dated
August 15, 1994, among the Company and the investors and the
founders named therein.
*10.1 - Form of Indemnification Agreement.
*10.2 - Series C Preferred Stock Purchase Agreement, dated July 16,
1993, as amended, among the Company and the investors named
therein.
*10.3 - Series D Preferred Stock Purchase Agreement, dated August
15, 1994, as amended, among the Company and the investors
named therein.
*10.4 - 1989 Stock Option Plan.
*10.5 - 1995 Stock Option Plan.
*10.6 - Employee Stock Purchase Plan.
*10.7 - 1996 Incentive Compensation Plan.
*10.8 - Employment agreement between the Company and W. James
Fitzsimmons.
*10.9 - Employment agreement between the Company and Victor M.
Bernhard.
*10.10 - Note Secured by Second Deed of Trust and Note Secured by
Stock Pledge Agreement between the Company and W. James
Fitzsimmons dated September 22, 1992.
*10.11 - Stock Pledge Agreements dated January 7, 1994, December 10,
1995 and December 13, 1995 between the Company and W. James
Fitzsimmons.
**10.12 - Lease by and between Menlo Business Park and Patrician
Associates, Inc. and the Company, as amended by First
Amendment to Lease Agreement, dated February 26, 1996.
**10.13 - Employment agreement between the Company and Ronald R.
Giannotti.
+11.0 - Computation of Loss Per Share
27.0 - Financial Data Schedule 5
</TABLE>
* Incorporated by reference from an exhibit to the Company's
Registration Statement on Form S-1, as amended, (File No.
33-80557) declared effective by the Commission on February
6, 1996
** Incorporated by reference from an exhibit to the Company
Annual Report on Form 10-K filed with the Commission on
March 29, 1996
+ Previously Filed with Form 10-Q on May 15, 1996
Page 4 of 5
<TABLE> <S> <C>
<ARTICLE> 5
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1996
<PERIOD-START> JAN-01-1996
<PERIOD-END> MAR-31-1996
<CASH> 2,887,018
<SECURITIES> 21,123,562
<RECEIVABLES> 97,000
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 24,957,645
<PP&E> 1,684,113
<DEPRECIATION> 587,422
<TOTAL-ASSETS> 31,043,422
<CURRENT-LIABILITIES> 1,893,956
<BONDS> 0
0
0
<COMMON> 83
<OTHER-SE> 29,149,383
<TOTAL-LIABILITY-AND-EQUITY> 31,043,422
<SALES> 103,000
<TOTAL-REVENUES> 103,000
<CGS> 117,040
<TOTAL-COSTS> 117,040
<OTHER-EXPENSES> 2,890,221
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (2,665,944)
<INCOME-TAX> 0
<INCOME-CONTINUING> 0
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (2,665,944)
<EPS-PRIMARY> (.35)
<EPS-DILUTED> (.35)
</TABLE>
